The short answer
Garlic bulb extract supplements deserve review while taking acalabrutinib, especially if you have low platelets or other bleeding risks. A direct increase in bleeding from this exact combination has not been measured.
What this answer covers
Oral acalabrutinib with garlic bulb extract supplements. Dose and exact preparation matter; food exposures and other plant parts are distinct.
- Supplement or preparation
- Allium Sativum (Garlic) Bulb Extract
- Medication ingredient
- acalabrutinib
Check the prescribed treatment
This review concerns oral acalabrutinib used for selected blood cancers. CALQUENCE tablets use the maleate salt, while capsules contain the free-base form. The formulations have different acid-reducer instructions, so follow the product actually prescribed and keep the full treatment regimen intact.
Why the team needs the product details
Acalabrutinib can cause serious bleeding or low platelet counts. Concentrated garlic supplements differ from food seasoning, and extraction can change the constituents present. The exact product and the rest of your medicines should be reviewed together.
What the human evidence does not prove
A small garlic-tablet trial found no significant platelet aggregation effect, although some participants reported bleeding at the highest dose. It compared garlic with aspirin rather than testing this combination. Tablet results and self-reports cannot establish the risk from every bulb extract.
Follow the monitoring and symptom plan
Report unusual bruising or persistent bleeding, and seek urgent help for major bleeding, black stools or vomiting blood. Keep the prescribed blood-count checks. Do not stop the cancer drug or rely on a gap between doses to prevent a possible effect on clotting.
Evidence and practical considerations
Side effects & toxicity
The drug bleeding warning and supplement-specific guidance support a conditional precaution, with human counterevidence retained.
- Exact scope
- Oral acalabrutinib with garlic bulb extract supplements. Dose and exact preparation matter; food exposures and other plant parts are distinct. with RxNorm 1986808 IN acalabrutinib. Exact current oral product: CALQUENCE oral acalabrutinib maleate tablets. Salt, formulation and regimen distinctions explicit.
- Medication form and route
- Oral
What remains uncertain
- No exact co-use bleeding-outcome trial. Conditional supplement-specific bridge; healthy or other-drug null results and formulation limits retained.
Factors that may matter: Exact oral formulation and supplement preparation; Drug exposure versus clinical outcomes; Dose and duration; Platelet count and neurological symptoms.
Read the supporting source summaries
Source 1: Current original prescribing information
dailymed.nlm.nih.gov · Source check Sep 11, 2026
Population: Patients prescribed the exact oral formulation.
Bleeding/low platelet warnings; CYP3A induction may lower exposure; maleate-tablet PPI null differs from capsule restriction.
How this applies: RxNorm 1986808 IN acalabrutinib. Exact current oral product: CALQUENCE oral acalabrutinib maleate tablets. Salt, formulation and regimen distinctions explicit.
Exact product source, not a direct study of every supplement. Population, active metabolites and formulation scope retained.
Source 2: Original official botanical guidance
nccih.nih.gov · Source check Sep 11, 2026
Population: Supplement users.
Supplements may increase bleeding risk; medicines and surgery warrant review.
How this applies: Conditional supplement bleeding precaution.
Not an exact cancer-drug trial or every extract.
Source 3: Original clinical research
pubmed.ncbi.nlm.nih.gov · Source check Sep 11, 2026
Population: Healthy volunteers in an open-label randomized trial.
No significant platelet aggregation effect detected; some self-reported bleeding at highest garlic dose.
How this applies: Exact preparation/population/endpoints only; applicability to acalabrutinib independently assessed.
Small trial; platelet tests and self-reports do not quantify major bleeding. Tablet preparation cannot represent all bulb extracts.
Source 4: Medication terminology
rxnav.nlm.nih.gov · Source check Sep 11, 2026
Population: Terminology.
acalabrutinib is IN.
How this applies: Exact ingredient.
Not clinical evidence.
Research assessment: · Open full citations ↗
Review and change history
- Publication status
- Published research summary
- Clinical review
- Not yet recorded
| Date | Update |
|---|---|
| Research summary published | |
| Article prepared | |
| Sources checked and article drafted. |
Article revision: 80abfc5a3341eeba
This guide brings together the evidence records used by our interaction checker. Each finding retains its own preparation limits, research date, and source summaries.
Full citations require verification. Reading this answer and the source summaries does not.
Taking other supplements or medications?
Use the checker to explore your other combinations. Ask a pharmacist to review the exact products, amounts and medical conditions in your complete list.
Open the interaction checkerInformation, not medical advice. Do not change prescribed treatment based on this guide.